Neurotrope, Inc. Common
NTRP
NTRP was delisted on the 1st of December, 2020.
16 hedge funds and large institutions have $7.78M invested in Neurotrope, Inc. Common in 2017 Q1 according to their latest regulatory filings, with 16 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tanaka Capital Management
New York
|
+$1.73M |
| 2 |
CC
Cannell & Co
New York
|
+$1.19M |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$860K |
| 4 |
OCMI
Oaktop Capital Management II
Chatham,
New Jersey
|
+$852K |
| 5 |
BFM
Boston Financial Management
Boston,
Massachusetts
|
+$829K |
Top Sellers
NTRP Hedge Fund Activity: Q1 2017 in Review
16 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Neurotrope, Inc. Common (NTRP) for Q1 2017, worth a combined $7.78M.
Buyers outnumbered sellers: 16 funds opened new NTRP positions and 0 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Tanaka Capital Management, opening a new position worth an estimated $1.73M.
- 16 institutional investors held Neurotrope, Inc. Common (NTRP) as of Q1 2017, up from 0 in Q4 2016.
- Funds reported $7.78M of Neurotrope, Inc. Common stock for Q1 2017.
- 16 funds opened new Neurotrope, Inc. Common positions in Q1 2017 and 0 closed out, a net change of +16 holders.
- The largest Neurotrope, Inc. Common buyer in Q1 2017 was Tanaka Capital Management, an estimated $1.73M added.
Based on aggregated 13F filings for Q1 2017.